<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29325508</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2041-6008</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Therapeutic delivery</Title>
          <ISOAbbreviation>Ther Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments.</ArticleTitle>
        <Pagination>
          <StartPage>121</StartPage>
          <EndPage>136</EndPage>
          <MedlinePgn>121-136</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4155/tde-2017-0102</ELocationID>
        <Abstract>
          <AbstractText>In the 24 years since first being marketed, the mesh nebulizer has been developed by five main manufacturers into a viable solution for the delivery of high-value nebulized drugs. Mesh nebulizers provide increased portability, convenience and energy efficiency along with similar lung deposition and increased ease of use compared with jet nebulizers. An analysis of EU and US clinical trial databases has shown that mesh nebulizers are now preferred over jet nebulizers for clinical trials sponsored by pharmaceutical companies. The results show a strong preference for the use of mesh nebulizers in trials involving high cost and niche therapy areas. Built-in capability to optimize the way patients use their mesh nebulizer and manage their disease will further increase uptake. [Formula: see text].</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pritchard</LastName>
            <ForeName>John N</ForeName>
            <Initials>JN</Initials>
            <AffiliationInfo>
              <Affiliation>Respironics Respiratory Drug Delivery (UK) Ltd, a business of Philips Electronics UK Limited, Chichester, West Sussex, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hatley</LastName>
            <ForeName>Ross Hm</ForeName>
            <Initials>RH</Initials>
            <AffiliationInfo>
              <Affiliation>Respironics Respiratory Drug Delivery (UK) Ltd, a business of Philips Electronics UK Limited, Chichester, West Sussex, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Denyer</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>PS5 Consultants Ltd, Portsmouth, Hampshire, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hollen</LastName>
            <ForeName>Dirk von</ForeName>
            <Initials>DV</Initials>
            <AffiliationInfo>
              <Affiliation>Respironics, Inc., a Philips Healthcare company, Murrysville, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Ther Deliv</MedlineTA>
        <NlmUniqueID>101538870</NlmUniqueID>
        <ISSNLinking>2041-5990</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009330" MajorTopicYN="N">Nebulizers and Vaporizers</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
          <QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">clinical trial registrations</Keyword>
        <Keyword MajorTopicYN="Y">manufacture</Keyword>
        <Keyword MajorTopicYN="Y">market uptake</Keyword>
        <Keyword MajorTopicYN="Y">mesh/jet</Keyword>
        <Keyword MajorTopicYN="Y">nebulizer</Keyword>
        <Keyword MajorTopicYN="Y">popularity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29325508</ArticleId>
        <ArticleId IdType="doi">10.4155/tde-2017-0102</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
